CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study (S50.002)

Conclusions:Treatment with CHS-131 was generally well-tolerated, and the 3mg dose resulted in a significant decrease in the incidence of new CE lesions as compared with placebo over 6 months.Study Supported by:This study was supported by a grant from the Ministry of Industry and Trade of the Russian Federation and sponsored by Coherus BioSciences and Zao InteKrin.Disclosure: Dr. Weinstein has received personal compensation for activities with InteKrin Therapeutics, Inc. and Coherus BioSciences as a consultant. Dr. Weinstein has received compensation for serving on the Board of Directors and the Scientific Advisory Board of RiverTown Therapeutics, Inc. Dr. Weinstein has received (royalty or license fee or contractual rights) payments from RiverTown Therapeutics Inc. Dr. Boyko has received personal compensation for activities with Biogen Idec, Sanofi-Genzyme, Novartis, Teva, Merck-Serono, and Takeda as a consultant, advisor or speaker. Dr. Pugliese has received personal compensation for activities with Coherus BioSciences as an employee. Dr. Pugliese holds stock in Coherus BioSciences. Dr. Tang has received personal compensation for activities with Coherus BioSciences as an employee. Dr. Tang holds stock and/or stock options in Coherus BioSciences. Dr. Lanfear has received personal compensation for activities with Coherus BioSciences as an employee. Dr. Lanfear holds stock and/or stock options in Coherus BioSciences. Dr. Zivadinov has received personal compensation for activiti...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Weinstein, D., Boyko, A., Pugliese, L., Tang, H., Lanfear, D., Zivadinov, R., Finck, B. Tags: MS Novel Therapeutics and Animal Models Source Type: research